Immunohistochemical evaluation of Leu-7, myelin basic-protein, S100-protein, glial-fibrillary acidic-protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas.
The collective expression of five antigens produced in immature or mature myelin-producing glia was evaluated in nerve sheath tumors and spindle cell sarcomas with histologic features of schwannomas. Myelin-associated glycoprotein (Leu-7), myelin basic-protein (MBP), S100-protein, and, in most cases, glial-fibrillary acidic-protein (GFAP) and HLA-DR/Ia (LN3) immunoreactivity were evaluated immunohistochemically using commercially available antibodies on 53 benign nerve sheath tumors and 12 sarcomas. Leu-7 immunoreactivity was detected by a monoclonal antibody in 12 of 16 schwannomas, 12 of 20 neurofibromas, and 17 of 17 traumatic neuromas. No Leu-7 positivity was seen in the sarcomas. Distinct heavy MBP immunoreactivity, assessed using polyclonal antibodies, was identified only in all 17 traumatic neuromas. Extensive S100-protein positivity was seen in 15 of 16 schwannomas, 17 of 20 neurofibromas, and 17 of 17 traumatic neuromas. Extensive LN3 immunoreactivity was seen in Schwann cells of 50% of the nerve sheath tumors analyzed; however, it was also present in associated interdigitating reticulum cells; GFAP immunoreactivity was not detected. These data suggest that Leu-7 is an important marker of Schwann cell neoplasms, although it is not superior to S100 protein. Moreover, combined immunohistochemical evaluation of potential Schwann cell markers including Leu-7, MBP, GFAP, and LN3 using commercially available antibodies offers no advantage over analysis of S100-protein immunoreactivity alone.
D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D005354:Fibrosarcoma / Q000032:analysis / Q000276:immunology; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007890:Leiomyosarcoma / Q000032:analysis / Q000276:immunology; D004676:Myelin Basic Protein / Q000032:analysis; D009185:Myelin Proteins / Q000032:analysis; D009186:Myelin Sheath / Q000032:analysis; D018992:Myelin-Associated Glycoprotein; D009363:Neoplasm Proteins / Q000032:analysis*; D009423:Nervous System Neoplasms / Q000032:analysis* / Q000276:immunology; D009442:Neurilemmoma / Q000032:analysis* / Q000276:immunology; D009455:Neurofibroma / Q000032:analysis / Q000276:immunology; D009418:S100 Proteins / Q000032:analysis; D012509:Sarcoma / Q000032:analysis* / Q000276:immunology; D012583:Schwann Cells / Q000032:analysis
D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D005904:Glial Fibrillary Acidic Protein; D000949:Histocompatibility Antigens Class II; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D009363:Neoplasm Proteins; D009418:S100 Proteins